Biogen and its partner rework terms of Aduhelm deal amid slow sales

Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer’s drug. Biogen, meanwhile, said the amended deal should make it easier to “address market developments.”